NCT01936350View on ClinicalTrials.gov

Sildenafil Impact on Ventricular Function in Patients With Heart Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Heart Failure
Interventions
DRUG

Sildenafil

The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.

DRUG

Placebo

This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.

Trial Locations (1)

40000

Hospital Ana Neri - MRI unit, Salvador

All Listed Sponsors
lead

Hospital Ana Nery

OTHER

NCT01936350 - Sildenafil Impact on Ventricular Function in Patients With Heart Failure | Biotech Hunter | Biotech Hunter